Epidemiology and risk factors for nosocomial Non-Candida albicans candidemia in adult patients at a tertiary care hospital in North China

Medical Mycology

Volumn 53, Issue 7, 2015, Pages 684-690

  Ding, Xiurong ^a   Yan, Donghui ^b   Sun, Wei ^b   Zeng, Zhaoyin ^b   Su, Ruirui ^b   Su, Jianrong ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

epidemiology; non albicans Candida species; Nosocomial candidemia; risk factor

Indexed keywords

PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; ARTIFICIAL BLOOD VESSEL; CANCER SURGERY; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CARDIOVASCULAR ARTIFICIAL ORGAN; CHINA; CLAVISPORA LUSITANIAE; CLINICAL FEATURE; CORONARY STENT; CYBERLINDNERA JADINII; DISEASE ASSOCIATION; DRUG EXPOSURE; ENDOPROSTHESIS; ESOPHAGEAL STENT; FEMALE; FEMORAL ARTERY STENT; HIGH RISK PATIENT; HIP PROSTHESIS; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INDEPENDENT VARIABLE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PICHIA KUDRIAVZEVII; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TERTIARY CARE CENTER; CANDIDA; CLASSIFICATION; CROSS INFECTION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CANDIDA; CANDIDEMIA; CHINA; CROSS INFECTION; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS;

EID: 84941210289     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmy/myv060     Document Type: Article

References (39)

1. WisplinghoffH, Bischoff T, Tallent SMet al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39(3): 309-317.
2. Marchetti O, Bille J, Fluckiger U et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004; 38(3): 311-320.
3. Leleu G, Aegerter P, Guidet B, College des Utilisateurs de Base de Donnees en R. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002; 17(3): 16 8-175.
4. Zaoutis TE, Argon J, Chu J et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41(9): 1232-1239.
5. Pappas PG,Rex JH,Lee J,et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Disj 2003, 37, 5, 634-643.
6. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48(12): 1695-1703.
7. Montagna MT, Caggiano G, Lovero G et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection 2013; 41(3): 645-653.
8. Mikulska M, Bassetti M, Ratto S et al. Invasive candidiasis in non-hematological patients. Mediterr JHematol Infect Dis 2011; 3(1): e2011007.
9. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 20 09; 48(5): 503-535.
10. Gafter-Gvili A, Vidal L, Goldberg E et al. Treatment of invasive candidal infections: systematic review and meta-Analysis. Mayo Clin Proc 2008; 83(9): 1011-1021.
11. Ostrosky-Zeichner L, Rex JH, Pappas PG et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003; 47(10): 3149-3154.
12. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a populationbase d active surveillance program. J Clin Microbiol 2004; 42(4): 1519-1527.
13. Tumbarello M, Posteraro B, Trecarichi EM et al. Biofilm production by Candida species and in adequate antifungal therapy as predictors of mortality for patients with andidemia. J Clin Microbiol 2007; 45(6): 1843-1850.
14. Melo AS, Bizerra FC, Freymuller E et al. Biofilm production and ev aluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex. Med Mycol 2011; 49(3): 253-262.
15. Serefhanoglu K, Timurkaynak F, Can F et al. Risk factors for candidemiawith non-Albicans Candida spp. in intensive care unit patients with end-stage renal disease on chronic hemodialysis. J Formos Med Assoc 2012; 111(6): 325-332.
16. Redding SW, Kirkpatrick WR, Dib O et al. The epidemiology of non-Albicans Candida in oropharyngeal candidiasis in HIV patients. Spec Care Dentist 2000; 20(5): 178-181.
17. Bodey GP, Mardani M, Hanna HA et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002; 112(5): 380-385.
18. Dimopoulos G, Ntziora F, Rachiotis G et al. Candida albicans versus non-Albicans intensive care unit-Acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 2008; 106(2): 523-529, table of contents.
19. Almirante B, Rodriguez D, Cuenca-Estrella M et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2006; 44(5): 1681-1685.
20. Wu JQ, Zhu LP, Ou XT et al. Epidemiology and risk factors for non-Candida albicans candidemia in non-neutropenic patients at a Chinese teaching hospital. Med Mycol 2011; 49(5): 552-555.
21. Ma CF, Li FQ, Shi LN et al. Surveillance study of species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China. BMC Infect Dis 2013; 13: 337.
22. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am2006; 20(3): 485-506.
23. Centers for Disease Control and Prevention. Invasive Candidiasis. http://www.cdc.gov/fungal/diseases/candidiasis/invasive/. Accessed on 2015-05-14.
24. Ostrosky-Zeichner L, Kullberg BJ, Bow EJ et al. Early treatment of candidemia in adults: a review. MedMycol 2011; 49(2): 113-120.
25. De Luca C, Guglielminetti M, Ferrario A et al. Candidemia: species involved, virulence factors and antimycotic susceptibility. New Microbiol 2012; 35(4): 459-468.
26. Zhang X B,Yu SJ,Yu JX,et al. Retrospective analysis of epidemiology and prognostic factors for candidemia at a hospital in China, 2000-2009 Jpn J Infect Dis 2012 65, 6, 510-515.
27. Chen YC, Chang SC, Luh KT et al. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother 2003; 52(1): 71-77.
28. Malani A, Hmoud J, Chiu L et al. Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 2005; 41(7): 975-981.
29. Wisplinghoff H, Ebbers J , Geurtz L et al. Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob Agents 2014; 43(1): 78-81.
30. 0. Cheng MF, Yang YL, Yao TJ et al. Risk factors for fatal candidemia caused by Candida albicans and non-Albicans Candida species. BMC Infect Dis 2005; 5: 22.
31. Playford EG, Marriott D, Nguyen Q et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-Albicans Candida spp. Crit Care Med 2008; 36(7): 2034-2039.
32. Chow JK, Golan Y, Ruthazer R et al. Factors associated with candidemia caused by non-Albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis 2008; 46(8): 1206-1213.
33. Holley A, Dulhunty J, Blot S et al. Temporal trends, risk factors and outcomes in albicans and non-Albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. Int J Antimicrob Agents 2009; 33(6): 554e1-e7.
34. Morace G, Borghi E. Fungal infections in ICU patients: epidemiology and the role of diagnostics. Minerva Anestesiol 2010; 76(11): 950-956.
35. Penk A, Pittrow L. Role of fluconazole in the long-term suppressive therapy of fungal infections in patients with artificial implants. Mycoses 1999; 42(Suppl 2): 91-96.
36. Kralovicova K, Spanik S, Oravcova E et al. Fungemia in cancer patients undergoing chemotherapy versus surgery: risk factors, etiology and outcome. Scand J Infect Dis 1997; 29(3): 301-304.
37. Li D, Zhang W, Zheng S et al. Surveillance study of candidemia in cancer patients in North China. MedMycol 2013; 51(4): 378-384.
38. Blumberg HM, Jarvis WR, Soucie JM et al. Risk factors for candidal bloodstream infections in surgical intensi ve care unit patients: the NEMIS prospectivemulticenter study. TheNational Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33(2): 177-186.
39. Arendrup MC, Sulim S, Holm A et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol 2011; 49(9): 3300-3308.